XBiotech Inc
For the period ended Dec 31, 2023. Filed Mar 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 15, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 16. FORM 10–K SUMMARY
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on March 15, 2024.
XBIOTECH INC.,
/s/ JOHN SIMARD
Name: John Simard
Title: President and Chief Executive Officer
(Principal Executive Officer)
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature and Title | Date |
|---|---|
| /s/ JOHN SIMARD | March 15, 2024 |
| John Simard, Chief Executive Officer (Principal Executive Officer) and Director | |
| /s/ ANGELA HU | March 15, 2024 |
| Angela Hu, Principal Financial Officer and Principal Accounting Officer | |
| /s/ W. THORPE MCKENZIE | March 15, 2024 |
| W. Thorpe McKenzie, Director | |
| /s/ JAN-PAUL WALDIN | March 15, 2024 |
| Jan-Paul Waldin, Director | |
| /s/ DONALD MACADAM | March 15, 2024 |
| Donald MacAdam, Director | |
| /s/ PETER LIBBY | March 15, 2024 |
| Peter Libby, Director | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.